Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 7

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 7
---
 QA/QC to meet EU standards, TGA standards in Australia, and that will meet World Class standards required by the FDA in the
United States. This strong pipeline and provenance will clarify and streamline licensing standards to issue all vertically integrated
licenses needed in each jurisdiction that we enter in each country. We plan to utilize the highest GMP standards for eventual sale to
the public, both for Domestic use and International export.

Under the continuation of
Phase 3 and for Phase 4 – assuming our human clinical trials proved to be successful, we plan for WEED Israel Cannabis Ltd., once
cleared and permitted by The Israeli Ministry of Health, to begin to move to manufacturing of product both for commercial pharmaceutical
and non-pharmaceutical uses. These above stated studies will include development of “educational courses” for continuing education
to medical professionals to attract; Drs. PHDs, pharmacists, pharmacist assistants and retail managers, pharmacy industry service providers,
pharmacy trade press, educators, government officials, students & new graduates, other pharmaceutical & health-related industry
professionals.

In addition, we plan for
proprietary strains of cannabis genetics to be imported & incorporated into our studies upon Ministry of Health authorization or lead
authorities globally for additional research and evaluation to complete DNA sequencing, Pathogen studies, Metabolic Studies, and MetaBolomics
analysis adding to our databases to increase efficiencies, worldwide. Our goal is to achieve a 38% - 40% THC (tetrahydrocannabinol) plant,
natural or enhanced genetics, to synthesis THC and THC-A to separate THC (pyschoactive) from THC-A (non-pyschoactive) to control dosing
for commercial release of products. We will conduct separate studies and evaluations for Cannabidiol (CBD), a phytocannabinoid. CBD does
not have the same psychoactivity as THC. CBD is one of 113 currently identified cannabinoids in the Cannabaceae plant. CBD accounts for
up to 40% of plant extracts.

This also requires the development
of continuing “Education Studies” to educate doctors and health practitioners on proper use as stated above for increased
bioavailability to achieve consistent controlled dosing for patients medical requirements and needs. This will require short and long
term, continual studies to supply proper medical advice and treatment to provide the highest quality medical and legal use products for
both humans and animal conditions and diseases. We will look to supply constant and continual medical information and products for preventative
t